
What drives long term survival with systemic treatment

Alberto Sobrero IRCCS San Martino IST, Genova

determinants of efficacy



What drives long term survival of mCRC

1. Relevance of pts and tumour related factors on outcome

2. Relevance of treatment on outcome

- The 4 different eras
- Impact of each individual drug
- How treatment can change the biology (i.e. tumor related factors)
- Clinical case

3. Median vs outlyers

Relevance of pts and tumour related factors on outcome

1. Koehne (Ann Oncol 1992) : when median OS was 11 months

- Poor 6 mo
- Intermediate 10 mo
- Good 14 mo

2. Chibaudel (The Oncol 2011) : when median OS was 22 months

- Poor 14 mo
- Intermediate 21 mo
- Good 27 mo

3. Now (ESMO 2014): median OS 30+ months

Relevance of pts and tumour related factors on outcome

Koehne (Ann Oncol 1992): when median OS was 11 months 1.

6

- Poor
- Intermediate ۲
- Good ۲

mo 10 mo

100%

Chibaudel (The Oncol 2011): when median OS was 22 months 2.

14 mo

- 14 mo Poor ۲ Intermediate 21 mo 100% \bullet
- Good 27 mo ۲
- Now (ESMO 2014): median OS 30+ months 3.

likely 100%

Relevance of treatment on outcome: the 4 different eras

era treatment	MST	gain vs no Rx	proportional gain
'1970' None	6	0	0
'1990 FU	12	6	100%
[•] 2000 doublets	20	14	240%
' now' biologics	30	24	500%

What drives long term survival of mCRC

1. Relevance of pts and tumour related factors on outcome

2. Relevance of treatment on outcome

- The 4 different eras
- Impact of each individual drug
- How treatment can change the biology (i.e. tumor related factors)
- Clinical case

3. Median vs outlyers


Toward the definition of the overall benefit of antineoplastic agents in advanced CRC

DRUG	1° line	other lines	'overall'
FU	6.0, 6.0, 2.2		5
IRI	2.0, 3.1, 3.2	2.7, 2.3	3
OXALI	1.5, 3.1, 4.5		3
BEV	4.7, 1.3, 3.7, 3	3. 9, 4.9 2. 5, 1.4	5
CET	3.5 ,4.3,-0.7,-0	0.7 0.7, 4.7	4
PANI	4.2	2.0, -0.1, 0.5	4
Extd RAS	1.5, 4.7, 3.8		4
AFLIB		1.4	1.4
REGO		1.4	1.4

Toward the definition of the overall benefit of antineoplastic agents in advanced CRC

DRUG	1° line	other lines	'overall'
FU	6.0, 6.0 2.2		5
IRI	2.0, 3.1, 3.2	2.7, 2.3	3
OXALI	1.5, 3.1, 4.5		3
BEV	4.7, 1.3, 3.7, 3.9	, 4.9 2.5, 1.4	5
CET	3.5 ,4.3,-0.7,-0.7	0.7, 4.7	4
PANI	4.2	2.0, -0.1, 0.5	5 4
Extd RAS	1.5, 4.7, 3.8		4
AFLIB		1.4	1.4
REGO		1.4	1.4

Male 66, stage III T3 G2 N1 5/23, colon, in 2009, adjuvant folfox



Feb 2010 Fatigue, fever, PS 1-2 CEA 1250

FOLFIRI + beva

Aug 2010 Asymptomatic, CEA 12 Cape +beva


feb 2011 Asymptomatic, CEA 15 ng/mL

Cape +beva

66 yo, Excellent PR to FOLFIRI BEVA and maintenance with cape beva for 12 months

August	2012	pause for 4 month	าร
January	2013	P Liver + N	\rightarrow rechallenge FOLFIRI for 3 months \rightarrow PR \rightarrow pause
August	2013	P Liver+N+Lung	\rightarrow cape 4 months \rightarrow SD , then pause 2 mo
Februar	2014	Р	\rightarrow FOLFOX for 3 mo \rightarrow minimal response
May	2014	MR	\rightarrow maintenance cape till now \rightarrow SD

Changing the natural history



What drives long term survival of mCRC

1. Relevance of pts and tumour related factors on outcome

2. Relevance of treatment on outcome

- The 4 different eras
- Impact of each individual drug
- How treatment can change the biology (i.e. tumor related factors)
- Clinical case

3. Median vs outlyers